Katherine D. Crew, MD, MS

Katherine D. Crew, MD, MS, discusses recent advances made in HER2-positive breast cancer treatment.

Katherine D. Crew, MD, MS, director of Clinical Breast Cancer Prevention Program, Columbia University Irving Medical Center, and director of DataBase Shared Resource at Herbert Irving Comprehensive Cancer Center, Columbia University, discusses updated data with margetuximab in HER2-positive breast cancer.

Katherine D. Crew, MD, MS, discusses the results of the APHINITY trial in HER2-positive breast cancer.